Data Sheet

Product Name:	Mivebresib
Cat. No.:	CS-5815
CAS No.:	1445993-26-9
Molecular Formula:	$C_{22}H_{19}F_2N_3O_4S$
Molecular Weight:	459.47
Target:	Apoptosis; Epigenetic Reader Domain
Pathway:	Apoptosis; Epigenetics
Solubility:	DMSO : 100 mg/mL (217.64 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Mivebresib (ABBV-075) is a potent and orally active **bromodomain and extraterminal domain (BET) bromodomain** inhibitor. Mivebresib binds to **BRD4** with a $\mathbf{K_i}$ of 1.5 nM[1]. IC50 & Target: IC50: 1.5 nM (BRD4)[1] **In Vitro:** Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1].

References:

[1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

CAIndexNames:

Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-

SMILES:

CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA